NCT01650415

Erythropoietin Therapy for Children With Cerebral Palsy

Random Control Trial to Evaluate the Safety and Efficacy of Erythropoietin Therapy for Children With Cerebral Palsy -Patient, Principle Investigator, Observer Blind

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 11 (actual)
• Sponsor: Bundang CHA Hospital · Academic / Other
• Sex: All
• Age: 4 Months – 4 Years
• Healthy volunteers: Not accepted

Summary

This randomized placebo-controlled trial aims to investigate the efficacy and safety of erythropoetin for children with cerebral palsy.

Detailed description

Cerebral palsy is a disorder of movement and posture resulted from a nonprogressive lesion or injury of the immature brain. It is a leading cause of childhood onset disability. Many experimental animal studies have revealed that erythropoietin is useful to repair neurological injury in brain. The main mechanism of erythropoietin is supposed as follows; 1. Neuroprotection effect 2. Angiogenesis 3. Anti-inflammation. On the basis of many experimental studies, erythropoietin is suggested as a therapeutic method for cerebral palsy.

Conditions

• Cerebral Palsy

Interventions

Type	Name	Description
DRUG	Erythropoietin	twice a week for 1 month
DRUG	Placebo erythropoietin	twice a week for 1 month

Timeline

• Start date: 2014-09-01
• Primary completion: 2015-02-01
• Completion: 2015-12-01
• First posted: 2012-07-26
• Last updated: 2017-10-12

Locations

1 site across 1 country: South Korea